weimar sepsis update 2009

[1]

German Sepsis Society [2]

 

Technical realization of the online Lectures was sponsored 

by

 

[3]

 

 

 

Presentations 

 

For the Author`s scientific profile at BIOMEDEXPERTS [4], please click author

Why sepsis goes public 

K. Reinhart [5]

Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Jena, Jena, Germany

Start Presentation [6]

 

Key Note Lecture: Sepsis as main cause of death in children

N. Kissoon [7]

Department of Pediatrics, University of British Columbia, Vancouver, Canada

Start Presentation [8]

 

 

Hot Topics

 

Why we need the CHEST trial on the safety and efficacy of HES 130/04

J. Myburgh [9]

Department of Intensive Care Medicine, The George Institute for International Health

Sydney, Australia

Start Presentation [10]

 

ICU patients with A/H1N1 influenca – experiences and unsolved problems

A. Kumar [11]

University of Manitoba, Health Sciences Centre, St. Boniface Hospital,Winnipeg, Manitoba, USA

Start Presentation  [12]

   

 

Nosocomial infections – an interdisciplinary challenge

Prevention of multiresistant bacteria – the Dutch experience

M. Bonten [13]

Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands

Start Presentation [14]

 

 

Prevention of sepsis

 

SDD versus SOD – when and how

M. Bonten [13]

Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands

Start Presentation [15]

 

Update and controversies on adjunctive therapies of sepsis

 

Update on corticosteroids

Ch. Sprung [16]

Department of Anesthesiology and Critical Care Medicine, Hadassah University Hospital Ein-Karem, Jerusalem, Israel

Start Presentation [17]

 

Anticoagulatory strategies – an update

S. Opal [18]

Division of Infectious Diseases, The Memorial Hospital of Rhode Island, Pawtucket, USA

Start Presentation [19]

 

Selenium

D. Heyland [20]

Department of Medicine, Kingston General Hospital, Kingston, Canada

Start Presentation [21]

 

 

To follow the lectures of the Lunchsymposium:

 

Selenium in Intensive Care from an International Point of View

 

sponsored by biosyn Arzneimittel GmbH [22], please contact Ms. Julia Staiger [23] at biosyn

 

Does early administration of selenium improve neurological

outcome after cardiac arrest?

Johann Reisinger, Austria

 

The possible role of selenium in the peri-operative period

Zsolt Molnár, Hungary

 

The first experience of using selenase in patients with long-term

unconscious stage

Ruslan Nazarov, Russia

 

 

Adjunctive therapy of sepsis – new promising therapeutic targets

 

Immunomodulatory therapy of sepsis

R. Hotchkiss [24]

Critical Care Division, Washington University School of Medicine, St. Louis, USA

Start Presentation  [25]

 

Immunglobulins in sepsis – how strong is the evidence

K. Werdan [26]

Universitätsklinik und Poliklinik für Innere Medizin III, Klinikum der MLU Halle-Wittenberg, Halle, Germany

Start Presentation [27]

 

Anti-Toll-like receptor strategies

R. R. Schumann [28]

Institut für Mikrobiologie und Hygiene, Charité – Universitätsmedizin Berlin, Berlin, Germany

Rational use of antimicrobials in sepsis

 

Indications for new generation antifungals

G. Maschmeyer [29]

Klinik für Hämatologie und Onkologie, Ernst-von-Bergmann-Klinikum, Potsdam, Germany

Start Presentation [30]

 

How can we bring evidence based medicine to the bedside

 

Pitfalls in the applicazion of clinical trial results

Ch. Natanson [31]

Critical Care Medicine Department, National Institutes of Health, Bethesda, USA

Start Presentation  [32]

 

How and why sepsis bundles reduce mortality

P. Dellinger [33]

Section of Critical Care Medicine, Cooper University Hospital, Camden, USA

Start Presentation [34]

 

Impact of sepsis bundles in Spain

A. Artigas Raventós

Medicina Intensiva, Corporació Sanitària Parc Taulí, Barcelona, Spain

Start Presentation  [35]

 

 

New insights in the pathophysiology of sepsis

 

Why sepsis patients die – mechanism of organ failure

R. Hotchkiss [24]

Critical Care Division, Washington University School of Medicine, St. Louis, USA

Start Presentation [36]

 

 

Prevention and treatment of organ dysfunction

 

Modulation of perfusion and oxygenation

G. Marx [37]

Fachübergreifende Klinik für operative Intensivmedizin Erwachsene,

Universitätsklinikum Aachen, Aachen, Germany

Start Presentation  [38]

 

Volume replacement

A. Meier-Hellmann [39]

Klinik für Anästhesie, Intensivmedizin und Schmerztherapie, Helios-Klinikum Erfurt GmbH, Erfurt, Germany

Start Presentation [40]

 

Lung injury

G. Bernard [41]

Office of Research, Vanderbilt University School of Medicine, Nashville, USA

Start Presentation [42]

 

 

Respiratory therapy in ALI

L. Gattinoni [43]

Dipartimento Terapia Intensiva, Università degli Studi di Milano, Milan, Italy

Start Presentation [44]

 

Drug therapy in ALI

W. Seeger [45]

Klinik für Innere Medizin II, Universitätsklinikum Giessen, Giessen, Germany

Start Presentation [46] 

 

Liver failure

M. Bauer [47]

Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Jena, Jena, Germany

Start Presentation [48] 

 

Renal replacement therapy

S. John

Medizinische Klinik 4, Universitätsklinikum Leipzig, Erlangen, Germany

Start Presentation  [49]

 

Metabolic control of sepsis

 

Prevention and treatment of metabolic failure

G. Gutierrez [50]

Pulmonary and Critical Care Medicine, The George Washington University Medical Center, Washington, USA

Start Presentation  [51]

 

Lessons from the NICE SUGAR trial

D. Heyland [20]

Department of Medicine, Kingston General Hospital, Kingston, Canada

Start Presentation  [52]

 

Tight glucose control – what remains for daily clinical practice

F. M. Brunkhorst [53]

Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Jena

Jena, Germany

Start Presentation  [49]

 

Clinical benefit of new and known sepsis markers

 

Risk assessment and progression markers

F. Bloos [54]

Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Jena

Jena, Germany

 

 

Procalcitonin for antibiotic stewardship

B. Müller

Klinik für Allgemeine Innere Medizin, Kantonsspital Aarau, Aargau, Switzerland

Start Presentation 

 

 

Transcriptomic signatures in SIRS and sepsis

M. Bauer [47]

Klinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Jena, Germany

Start Presentation [55]